Update on the optimal use of bortezomib in the treatment of multiple myeloma.
Mohan M et al. Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017.

Multiple Myeloma: Diagnosis and Treatment.
Michels TC et al. Am Fam Physician. 2017 Mar 15;95(6):373-383.

Monoclonal antibody therapy in multiple myeloma.
Touzeau C et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.60. [Epub ahead of print].

Patients with myeloma need more time to ask questions.
Watts A et al. Nurs Stand. 2017 Mar 8;31(28):31. doi: 10.7748/ns.31.28.31.s28.

The Evolution of Prognostic Factors in Multiple Myeloma.
Hanbali A et al. Adv Hematol. 2017;2017:4812637. doi: 10.1155/2017/4812637.

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Dingli D et al. Mayo Clin Proc. 2017 Mar 10. pii: S0025-6196(17)30028-9. doi: 10.1016/j.mayocp.2017.01.003. [Epub ahead of print].

Current Review on High-Risk Multiple Myeloma.
Chan HS et al. Curr Hematol Malig Rep. 2017 Mar 20. doi: 10.1007/s11899-017-0368-z. [Epub ahead of print].

The Critical Role of Imaging in the Management of Multiple Myeloma.
Raza S et al. Curr Hematol Malig Rep. 2017 Mar 20. doi: 10.1007/s11899-017-0379-9. [Epub ahead of print].

Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry.
Palmaro A et al. Medicine (Baltimore). 2017 Mar;96(12):e6189. doi: 10.1097/MD.0000000000006189.

Mechanisms of Resistance in Multiple Myeloma.
Papadas A et al. Handb Exp Pharmacol. 2017 Mar 18. doi: 10.1007/164_2017_10. [Epub ahead of print].

Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial.
Robinson D Jr et al. Eur J Haematol. 2017 Mar 17. doi: 10.1111/ejh.12876. [Epub ahead of print].

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Leleu X et al. Blood Cancer J. 2017 Mar 17;7(3):e543. doi: 10.1038/bcj.2017.20.

Pharmacologic ascorbate in myeloma treatment: Doses matter.
Violet PC et al. EBioMedicine. 2017 Mar 9. pii: S2352-3964(17)30101-9. doi: 10.1016/j.ebiom.2017.03.014. [Epub ahead of print].

The high price of anticancer drugs: origins, implications, barriers, solutions.
Prasad V et al. Nat Rev Clin Oncol. 2017 Mar 14. doi: 10.1038/nrclinonc.2017.31. [Epub ahead of print].

Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.
Bashir Q et al. Curr Hematol Malig Rep. 2017 Mar 11. doi: 10.1007/s11899-017-0374-1. [Epub ahead of print].

Response Assessment in Myeloma: Practical Manual on Consistent reporting in an era of dramatic therapeutic advances.
Garderet L et al. Biol Blood Marrow Transplant. 2017 Mar 8. pii: S1083-8791(17)30327-0. doi: 10.1016/j.bbmt.2017.03.009. [Epub ahead of print].

Electrophoresis test prevalence, requesting patterns, yield and related bone marrow biopsy findings at a South African tertiary hospital: A 5-year retrospective audit.
Naidoo N et al. S Afr Med J. 2017 Feb 27;107(3):270-273. doi: 10.7196/SAMJ.2017.v107i3.10960.

A systematic review of health-related quality of life in longitudinal studies of myeloma patients.
Nielsen LK et al. Eur J Haematol. 2017 Mar 21. doi: 10.1111/ejh.12882. [Epub ahead of print].

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.
Oortgiesen BE et al. Eur J Clin Pharmacol. 2017 Mar 3. doi: 10.1007/s00228-017-2227-1. [Epub ahead of print].

Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
Ahn JS et al. J Clin Pathol. 2017 Mar 1. pii: jclinpath-2016-204294. doi: 10.1136/jclinpath-2016-204294. [Epub ahead of print].

Adiposity and cancer at major anatomical sites: umbrella review of the literature.
Kyrgiou M et al. BMJ. 2017 Feb 28;356:j477. doi: 10.1136/bmj.j477.

Patients’ Experiences With Multiple Myeloma: A Meta-Aggregation of Qualitative Studies.
Hauksdóttir B et al. Oncol Nurs Forum. 2017 Mar 1;44(2):E64-E81. doi: 10.1188/17.ONF.E64-E81.